

in the diagnosis of bone tumours based on routinely processed material.

References

- Ciplea AG, Metze K, Grundmann E, Roessner A, Hettwer H (1985) Microphotometric quantitation of enzyme activities in giant cell tumor of bone. *Pathol Res Pract* 179:412–418
- Metze K, Ciplea AG, Hettwer H, Barckhaus RH (1987a) Size dependent enzyme activities of multinucleated (osteoclastic) giant cells in bone tumors. *Pathol Res Pract* 182:214–221
- Metze K, Hettwer H, Roessner A (1987b) Ultrastructural and enzyme histochemical characteristics and their functional relationship in osteoclastic giant cells of bone tumors. *Pathol Res Pract* 182:525
- Toyosawa S, Ogawa Y, Chang CK, Hong SS, Yagi T, Kuwahara H, Wakasa KI, Sakurai M (1991) Histochemistry of tartrate-resistant acid phosphatase and carbonic anhydrase isoenzyme II in osteoclast-like giant cells in bone tumors. *Virchows Arch [A]* 418:255–261

Reply

S. Toyosawa

Department of Oral Pathology, Osaka University, Faculty of Dentistry, 1–8 Yamadaoka, Suita, Osaka 565, Japan

In reply to the comments made by Dr. Metze on our recent paper (Toyosawa et al. 1991), we would like to refer to two critical points.

To our knowledge, there have been few reports concerning the cell size of osteoclast-like giant cells in tumours and we have read their papers with great interest (Ciplea et al. 1985; Metze et al. 1987a, b). Among bone tumours containing osteoclast-like giant cells, that is to say, giant cell tumour (GCT), chondroblastoma, osteoblastoma and osteosarcoma, they have examined only GCT and osteosarcoma and only one case of each. In the 1987 paper (Metze et al. 1987a), they wrote: "Data reveal a similar distribution of cell size in each class of the different tumours" without actually showing data (such as a frequency distribution diagram). Moreover, they have analysed both cell size and tartrate-resistant acid phosphatase (TRAP) activity using an atypical or modified osteosarcoma after preoperative chemotherapy. It is well known that chemotherapy tends to change conventional osteosarcoma to atypical osteosarcoma mimicking the telangiectatic form in which large osteoclast-like giant cells are always present (Dahlin and Unni 1986; Mirra et al. 1989). Therefore, their opinion with respect to the cell size of osteoclast-like giant cells in bone tumours can not be justified by data or generalized for typical tumours. As Troup et al. (1960) have pointed out, large osteoclast-like cells may be encountered occasionally in conventional osteosarcoma, but their incidence in osteosarcoma is very low compared with that

in GCT. In our study, we selected and used material which exhibited the typical histology of each lesion (as shown in Fig. 1 in our paper). In general, the osteoclast-like giant cells in GCT were largest with the largest number of nuclei, whereas those in conventional or osteoblastic osteosarcoma were smallest with the smallest number of nuclei. The osteoclast-like giant cells in chondroblastoma appeared to be larger than those in osteoblastoma. TRAP activity was stronger in the larger cells in GCT and chondroblastoma than in the smaller cells in osteoblastoma and osteosarcoma. Our data therefore support Dr. Metze's attractive idea that GCT and chondroblastoma cells have stronger TRAP activity than osteoblastoma and osteosarcoma cells because the former have larger multinucleated cells than the latter, to some extent. Unfortunately, however, we did not quantitate the correlation between cell size and TRAP activity, while Dr. Metze's data cover only one example of each of two atypical tumours. The carbonic anhydrase II (CA II) immunohistochemistry is the only histochemical distinction between the two populations justified so far.

We now refer to the second point. The materials examined were fixed in neutral buffered formalin for 4–6 h, undecalcified, dehydrated through graded ethanols and embedded in 55–60° C paraffin. For histochemistry, we believe that extreme conditions such as decalcification or paraffin embedding at extremely high temperature or low temperature should be explained in the text. We omitted the details simply because the routine histology for clinical pathology does not include these extreme conditions. To date, most of the immunohistochemical studies of CA have been carried out using routinely processed, paraffin-embedded materials. Though Carnoy's fixative provides optimal immunostaining, aldehyde fixatives also provide good retention of affinity for anti-CA antibody (Hennigar et al. 1983; Kuwahara et al. 1983). Moreover, we employed the highly sensitive ABC technique (Hsu et al. 1981) to demonstrate immunoreactivity for CA II. Therefore, our materials and histochemistry can be considered to be suitable for the demonstration of CA immunoreactivity. More importantly, the present immunohistochemistry using routine histological preparations has clearly distinguished the osteoclast-like giant cells in GCT and chondroblastoma from those in osteoblastoma and osteosarcoma: the former, like osteoclasts, are positive for CA II, whereas the latter are negative.

In summary, we do not feel that Dr. Metze's comments are justified. They vitiate neither our experimental results nor the conclusions which we have obtained.

References

- Ciplea AG, Metze K, Grundmann E, Roessner A, Hettwer H (1985) Microphotometric quantitation of enzyme activities in giant cell tumor of bone. *Pathol Res Pract* 179:412–418
- Dahlin DC, Unni KK (1986) Bone tumors, 4th edn. Thomas, Springfield, pp 290–292
- Hennigar RA, Schulte BA, Spicer SS (1983) Immunolocalization of carbonic anhydrase isozymes in rat and mouse salivary and exorbital lacrimal glands. *Anat Rec* 207:605–614

- Hsu SM, Raine L, Fanger H (1981) Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase technique: a comparison between ABC and unlabeled antibody (PAP) procedures. *J Histochem Cytochem* 29:577-580
- Kuwahara H, Shimazaki M, Mitsuhashi T, Chanoki Y, Ogawa Y, Yagi T, Nakura K, Ishida T, Shimazu A (1983) Immunohistochemical demonstration of carbonic anhydrase in human kidney, bone and giant cell tumor of bone. *Osaka City Med J* 29:169-177
- Metze K, Ciplea AG, Hettwer H, Barckhaus RH (1987a) Size dependent enzyme activities of multinucleated (osteoclastic) giant cells in bone tumors. *Pathol Res Pract* 182:214-221
- Metze K, Hettwer H, Roessner A (1987b) Ultrastructural and enzyme histochemical characteristics and their functional relationship in osteoclastic giant cells of bone tumors. *Pathol Res Pract* 182:525
- Mirra JM, Picci P, Gold RH (1989) Bone tumors, clinical, radiologic, and pathologic correlations. Lea and Febiger, Philadelphia, pp 316-325
- Toyosawa S, Ogawa Y, Chang CK, Hong SS, Yagi T, Kuwahara H, Wakasa KI, Sakurai M (1991) Histochemistry of tartrate-resistant acid phosphatase and carbonic anhydrase isoenzyme II in osteoclast-like giant cells in bone tumours. *Virchows Arch [A]* 418:255-261
- Troup JB, Dahlin DC, Coventry MB (1960) The significance of giant cells in osteogenic sarcoma; do they indicate a relationship between osteogenic sarcoma and giant cell tumor of bone? *Proc Staff Meet Mayo Clin* 35:179-186